151. TgVax452, an epitope-based candidate vaccine targeting Toxoplasma gondii tachyzoite-specific SAG1-related sequence (SRS) proteins: immunoinformatics, structural simulations and experimental evidence-based approaches.
- Author
-
Majidiani H, Pourseif MM, Kordi B, Sadeghi MR, and Najafi A
- Subjects
- Animals, Mice, Female, Antibodies, Protozoan immunology, Mice, Inbred BALB C, Epitopes, B-Lymphocyte immunology, Epitopes, B-Lymphocyte genetics, Epitopes, B-Lymphocyte chemistry, Humans, Molecular Dynamics Simulation, Immunodominant Epitopes immunology, Immunodominant Epitopes genetics, Immunodominant Epitopes chemistry, Toxoplasmosis prevention & control, Toxoplasmosis immunology, Immunoinformatics, Protozoan Proteins immunology, Protozoan Proteins genetics, Protozoan Proteins chemistry, Toxoplasma immunology, Toxoplasma genetics, Toxoplasma chemistry, Protozoan Vaccines immunology, Protozoan Vaccines genetics, Antigens, Protozoan immunology, Antigens, Protozoan genetics, Antigens, Protozoan chemistry, Computational Biology, Epitopes, T-Lymphocyte immunology, Epitopes, T-Lymphocyte genetics
- Abstract
Background: The highly expressed surface antigen 1 (SAG1)-related sequence (SRS) proteins of T. gondii tachyzoites, as a widespread zoonotic parasite, are critical for host cell invasion and represent promising vaccine targets. In this study, we employed a computer-aided multi-method approach for in silico design and evaluation of TgVax452, an epitope-based candidate vaccine against T. gondii tachyzoite-specific SRS proteins., Methods: Using immunoinformatics web-based tools, structural modeling, and static/dynamic molecular simulations, we identified and screened B- and T-cell immunodominant epitopes and predicted TgVax452's antigenicity, stability, safety, adjuvanticity, and physico-chemical properties., Results: The designed protein possessed 452 residues, a MW of 44.07 kDa, an alkaline pI (6.7), good stability (33.20), solubility (0.498), and antigenicity (0.9639) with no allergenicity. Comprehensive molecular dynamic (MD) simulation analyses confirmed the stable interaction (average potential energy: 3.3799 × 10
6 KJ/mol) between the TLR4 agonist residues (RS09 peptide) of the TgVax452 in interaction with human TLR4, potentially activating innate immune responses. Also, a dramatic increase was observed in specific antibodies (IgM and IgG), cytokines (IFN-γ), and lymphocyte responses, based on C-ImmSim outputs. Finally, we optimized TgVax452's codon adaptation and mRNA secondary structure for efficient expression in E. coli BL21 expression machinery., Conclusion: Our findings suggest that TgVax452 is a promising candidate vaccine against T. gondii tachyzoite-specific SRS proteins and requires further experimental studies for its potential use in preclinical trials., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF